Synthetic Blood Announces Progress With Oxycyte Program In Traumatic Brain Injury

Synthetic Blood International, Inc. (OTCBB:SYBD) announced its plan to finalize a Phase IIb clinical trial protocol with Oxycyte? for the treatment of traumatic brain injury (TBI) at its Scientific Advisory Board (SAB) meeting scheduled for Thursday, December 13, 2007. Oxycyte is Synthetic Blood’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 15th, 2007